Merck's Recent Surge Sparks Caution Among Analysts
Merck's stock price has risen by 29.6% over the past six months, reaching $149.98 and surpassing the S&P 500 by 13.4%. However, despite this impressive performance, analysts are cautious about investing in the company due to several concerns.
The first concern is weak constant currency growth, which averaged 3.8% year-on-year over the last two years. This suggests that Merck may need to lower prices or invest in product improvements to accelerate growth, potentially hindering near-term profitability.
Additionally, Merck's adjusted operating margin has decreased by 19.9 percentage points over the last five years, raising questions about the company's expense base. Despite revenue growth of 7.9% over this period, earnings per share have declined by 11.1%, indicating a decrease in profitability on a per-share basis.
Considering these factors, analysts do not see a big opportunity in Merck at present and recommend looking for alternative investment options.